Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

3291 Study Matches

Sorting by: Relevance Distance

Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

Michael Olson
All
22 years and over
This study is NOT accepting healthy volunteers
0000-122000-P01-RST
19-003128
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Any patient implanted with or receiving an Inspire implant, who meets the following criteria, is eligible to participate in the registry:

  • Must be a legal adult, ≥ 22 years old.
  • Capable of giving informed consent, as required per institution.
  • Willing to return for routine clinic visits as required for Inspire therapy management.


Exclusion Criteria:

Any patient who meets any of the following criteria will not be eligible to participate in the registry:

  • Has a life expectancy of less than 1 year.
  • Any reason the clinician deems patient is unfit for participation in the study.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Advanced Multiparametric MR Elastography (MRE) in Evaluating and Monitoring the Hepatitis Activity in Patients with Hepatitis C Virus Infection

A Study to Evaluate and Monitor Hepatitis Activity in Hepatitis C Virus Infection Patients Using Advanced Multiparametric MR Elastography (MRE)

Douglas Simonetto
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122008-H01-RST
19-003168
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Diagnosis of HCV infection with laboratory test and verified by histological examination.
  • Liver MRE was performed within 3 months of histological analysis.
  • Age ≥ 18 years old.


Exclusion Criteria:
 

  • Patients with HBV coinfection (10% a high risk of parenteral transmission).
  • Perinatal transmission (because of the immature immunity system, the infection becomes chronic much easily; cause delayed virus clearance).
  • Patients with HIV infection (lower immune activity).
  • Patients have alcohol abuse.
  • Patients have antiviral treatment between liver biopsy and MRE examination.
  • Any medical condition that, in the opinion of the Principal Investigator, would serve as exclusion criteria for study enrollment.
General infectious diseases, Hepatitis C
Digestive system, MRI, Magnetic resonance elastography, Viral hepatitis C
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

A Study to Investigate Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Dmitry Esterov
All
18 years to 70 years old
Not Applicable
This study is NOT accepting healthy volunteers
0000-122010-H01-RST
19-003200
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


- Have a diagnosis of acute PTH attributed to mild traumatic injury to the head as
defined by the International Classification of Headache Disorders (ICHD-3).

- PTH onset 7-28 days prior to the time of enrollment

- Adults 18-70 years of age

- Willing to be randomized to either of the two clinical trial treatment arms

- Willing to maintain a headache diary

- Willing and able to return for follow-up visits

- 5 or more moderate or severe headache days during the 4-week run-in phase

- At least 80% compliant with diary keeping during the 4-week run-in phase (i.e.,
provides data on at least 80% of days)


Exclusion Criteria:


- Episodic tension-type headache, migraine, or other headaches with at least 4 headache
days/month on average over the 6 months prior to the mTBI resulting in PTH

- Previous history of chronic headache (i.e., at least 15 headache days/month) including
PPTH, chronic migraine, medication overuse headache, new daily persistent headache,
hemicrania continua, chronic tension-type headache

- Diminished decision-making capacity that in the investigator's opinion would interfere
with the person's ability to provide informed consent and complete study procedures

- Current or prior use of preventive medications for migraine or other primary headache
disorder

- Use of onabotulinumtoxinA in the head, neck or face region within 12 months of
screening

- During the 6 months before screening, use of opioids or barbiturates on an average of
at least 4 days per month

- Subjects who underwent an intervention or used a device (e.g., nerve blocks,
transcranial magnetic stimulation, vagal nerve stimulation, or electrical trigeminal
nerve stimulation) for headache

- History of major psychiatric disorder such as schizophrenia and bipolar disorder

- History or evidence of any unstable or clinically significant medical condition, that
in the opinion of the investigator, would pose a risk to subject safety or interfere
with the study evaluation, procedures, or completion

- History of positive neuroimaging findings that indicate a moderate or severe TBI

- Contraindications to magnetic resonance imaging, including, but not limited to (only
an exclusion for patients participating in the brain MRI portion of this research):

1. Metal implants

2. Aneurysm clips

3. Severe claustrophobia

4. Implanted electronic device

5. Insulin or infusion pump

6. Cochlear/otologic/ear implant

7. Non-removable prosthesis

8. Implanted shunts/catheters

9. Certain intrauterine devices

10. Tattooed makeup

11. Body piercings that cannot be removed

12. Metal fragments

13. Wire sutures or metal staples

- Factors that reduce MR image quality and interpretability (only an exclusion for
patients participating in the brain MRI portion of this research):

1. Dental braces or other non-removable devices (e.g., retainers)

2. Prior brain surgery

3. Known brain MRI abnormality that in the investigator's opinion will significantly
impact MRI data

- Sensory disorders that in the investigator's opinion might affect perception of
cutaneous thermal stimuli (e.g., peripheral neuropathy) (only an exclusion for
patients participating in the neurophysiology studies)

- Pregnancy

- Breastfeeding

- History of myocardial infarction, stroke, transient ischemic attack, unstable angina,
coronary artery bypass surgery, or other revascularization procedures within 12 months
prior to screening.

- Not willing to use a reliable form of contraception (for women of childbearing
potential) through 16 weeks after the last dose of erenumab. Acceptable methods of
birth control include not having intercourse, hormonal birth control methods,
intrauterine devices, surgical contraceptive methods, or two barrier methods (each
partner must use a barrier method) with spermicide. A reliable form of contraception
must be started prior to or at the time of starting the run-in phase. Not being of
childbearing potential is defined as any woman who is post-menopausal by history,
defined as:

1. At least 55 years of age with cessation of menses for 12 or more months; OR

2. Younger than 55 years of age but no spontaneous menses for at least 2 years; OR

3. Younger than 55 years of age and spontaneous menses within the past 1 year, but
currently amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND with
postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating
hormone levels at least 40 IU/L) or postmenopausal estradiol level (less than 5
ng/dL) or according to the definition of "postmenopausal range" for the
laboratory involved; OR

4. Underwent bilateral oophorectomy; OR

5. Underwent hysterectomy; OR

6. Underwent bilateral salpingectomy.

- Currently or within 90 days prior to screening: received treatment in another drug
study or an investigational device study

- Has previously received any CGRP ligand or receptor targeted monoclonal antibody

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/25/22. Questions regarding updates should be directed to the study team contact.

Other
Chronic daily headache, Concussion, Head and brain injury, Head injury, Headache NOS, Traumatic brain injury, Traumatic injury
Chronic post-traumatic headache, Concussion injury of brain, Nervous system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Pilot Study of Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma

A Study to Evaluate Circulating Cell Free Tumor DNA as a Biomarker in Sarcoma

Brittany Siontis
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122011-H01-RST
19-003215
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age 18 years old and older.
  • Advanced or metastatic bone or soft tissue sarcoma with a known translocation.
  • Evidence of disease progression or recurrence prior to initiation of systemic therapy.
  • No systemic therapy or major surgery within the past 30 days.
  • Willingness to provide blood and urine samples.
  • The absence of a second active malignancy.
  • An understanding of the protocol and its requirements, risks and discomforts.
  • Ability and willingness to sign an informed consent.

Exclusion Criteria

  • Pregnancy or lactation.
  • Inability to understand the informed consent.
Bone cancer, Cancer, Recurrent cancer, Sarcoma, Soft tissue sarcoma
Carrier of chromosome translocation, Medical Oncology, Musculoskeletal system, Sarcoma of soft tissue
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Randomized Controlled Trial of Electroconvulsive Therapy plus Usual Care versus Simulated-ECT plus Usual Care for the Acute Management of Severe Agitation in Alzheimer's Dementia (ECT-AD) (ECT-AD)

Electroconvulsive Therapy in Severe Agitation in Alzheimer's Dementia

Maria Lapid
All
55 years to 89 years old
Not Applicable
This study is NOT accepting healthy volunteers
0000-122017-H01-RST
19-003289
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Diagnosis of Alzheimer’s Dementia according to NIA-AA Criteria for dementia.
  • MMSE ≤ 15.
  • Cohen-Mansfield Agitation Inventory Nursing Home Version (CMAI) score of >5 on at least one item of aggression or a physical nonaggressive item that holds potentially dangerous consequences including hitting (including self), kicking, grabbing onto people, pushing, throwing things, biting, scratching, spitting, hurting self or other, tearing things or destroying property, making physical sexual advances, trying to get to a different place, intentional falling, screaming, making verbal sexual advances, and cursing or verbal aggression (items 1-11, 14, 15, 22-24).
  • At least three failed pharmacological interventions from different drug classes (including antidepressants, antipsychotics, anticonvulsants, prazosin, and cannabinoids) at therapeutic doses (to be determined by clinical judgment) and duration of at least two weeks each to manage behavioral symptoms. These interventions may also include medications discontinued after 1 week due to tolerability concerns. Furthermore, medication trials that occur prior to admission to the hospital may count towards the three failed trials. The trials can be inpatient and/or outpatient. These trials can also be concurrent, such as using two medications from different classes for at least one week  at the same time (i.e., polypharmacy).
  • Medically stable for safe administration of ECT verified by standard physical examination, urinalysis and serum chemistries.
  • Comprehension of English language.
  • Authorized legal representative able and willing to give informed consent.
  • Age 55
    •89 years old (inclusive).


Exclusion Criteria:

  • Current diagnosis of co-morbid delirium, measured by the Confusion Assessment Method (CAM) and by clinical diagnosis.
  • Diagnosis of Non-AD Dementia.
  • Lifetime or current diagnosis of Schizophrenia, Bipolar Disorder or Schizoaffective Disorder.
  • Active substance use disorder within past 6 months.
  • Treatment with ECT or other neurostimulation therapies (e.g., TMS or vagal nerve stimulation) within the past 3 months.
Behavioral
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

ALSENLITE: An Open-label Pilot Study of Senolytics for Alzheimer's Disease (ALSENLITE)

ALSENLITE: Senolytics for Alzheimer's Disease

Vijay Ramanan
All
55 years and over
Phase 1/2
This study is NOT accepting healthy volunteers
0000-122031-P01-RST
19-003394
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


1. Men and women of age 55 years and older at the time of enrollment

2. Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental
Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2,
inclusive)

3. Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors
and/or memantine, on a stable dose for at least three months

4. Body Mass Index (BMI) within range of 19
•50 kg/ m2

5. Participants must be accompanied by a LAR designated to sign informed consent and to
provide study partner reported outcomes at all visits

6. Participants must have no plans to travel over the ~3 months between Visits 3 and 14
that interfere with study visits

7. Tau positivity by brain PET imaging

8. Adequate blood counts i.e. platelets > 50,000 per microliter; HB > 9/dL, and ANC >
1000 per microliter

9. Availability and consent from a LAR.


Exclusion Criteria:


1. Unwilling or unable to give informed consent

2. Pregnancy

3. QTc > 450 msec on baseline ECG

4. MRI contraindications

5. Presence of uncontrolled psychiatric disorder (as per clinical judgment)

6. Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)

7. Substance or alcohol abuse (current alcohol use > 3 alcoholic beverage/day or > 21 per
week and as per clinical judgment)

8. Hearing, vision, or motor deficits despite corrective devices (as per clinical
judgment)

9. Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6
months

10. Chronic heart failure (as per clinical judgment)

11. Neurologic, musculoskeletal, or other condition that limits subject's ability to
complete study physical assessments (as per clinical judgment)

12. Positive SARS-CoV-2 test within 30 days prior to enrollment

13. AST/ALT > 2.5x upper limit normal

14. Presence of significant liver disease with total bilirubin > 2X upper limit or as per
clinical judgment

15. Inability to tolerate oral medication (as per clinical judgment)

16. Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per
clinical judgment

17. Malabsorption (as per clinical judgment)

18. Known human immunodeficiency virus infection (as per clinical judgment)

19. Known active hepatitis B or C infection

20. Invasive fungal or viral infection (as per clinical judgment)

21. Known hypersensitivity or allergy to D or Q

22. Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)

23. New/active invasive cancer except non-melanoma skin cancers

24. Inability to tolerate oral medications (as per clinical judgment)

25. Currently taking AND unable to safely hold any of the medications listed in Appendix 1
during the days IP is administered and for 36 hours after IP administration.

26. Uncontrolled diabetes (defined as HbA1c > 7% or as per clinical judgment).

27. Gastric bypass/reduction

28. Crohn's disease

29. Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase
or ESR) (as per clinical judgment)

30. eGFR < 10 ml/ min/ 1.73 m2

31. Creatinine clearance < 60 mL/min/1.73 m2

32. Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low
molecular weight heparin, factor Xa inhibitors, etc.)

33. On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81
mg), if absolutely necessary from cardiac perspective, will be allowed

34. Presence of any condition that the Investigator believes would put the subject at risk
or would preclude the patient from successfully completing all aspects of the trial

Involvement of special vulnerable populations: We will not involve special vulnerable
populations, such as fetuses, neonates, pregnant women, children, prisoners,
institutionalized individuals, or others who may be considered vulnerable populations
except for patients with dementia. Therefore, availability and consent from a LAR is an
inclusion criterion.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/20/22. Questions regarding updates should be directed to the study team contact.

Drug
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Nicotine Concentrations During Hookah Smoking Sessions in Regular Hookah Smokers

A Study to Evaluate Nicotine Concentrations in Regular Hookah Smokers

Jon Ebbert
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122034-H01-RST
19-003417
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Smokers of Hookah (shisha tobacco).
  • 18 years of age or older.
  • Able to participate fully in all aspects of the study.
  • Understand and verbally consent to participate in the study.
  • Has the ability to have 25 cc of blood drawn over the course of 2 hours through a catheter.


Exclusion Criteria:

  • Study subjects not meeting the Inclusion Criteria above.
Nicotine dependence
Hookah pipe, Hookah pipe smoker, Nicotine dependence
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Joint Preservation (JP) Repository 2: A Multi-Center Cohort Investigating Surgical Outcomes and Predictors of Treatment for Hip Disease

A Study to Analyze Surgical Outcomes and Predictors of Treatment for Hip Diseases

Rafael Sierra
All
9 years and over
Not Applicable
This study is NOT accepting healthy volunteers
0000-122044-P01-RST
19-003519
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Ages 9+ years old.
  • Scheduled for surgical intervention (e.g., joint preservation surgery).


Exclusion Criteria:

  • Unable to consent due to mental faculty.
  • Pregnant women.
  • Non-English speaking patients.
  • Prisoners or other vulnerable populations.
Radiation, Operative procedure on hip, Procedure on hip joint, Research data collection
Arthritis, Hip pain, Osteoarthritis, Hip arthritis, Hip instability
Arthritis of hip, Disorder of hip joint, Hip preservation surgery, Hip replacement, Hip unstable, Joint replacement, Musculoskeletal system, Joint replacement surgery
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Circulating Tumor DNA (ctDNA) and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer

A Study to Evaluate Circulating Tumor DNA (ctDNA) and Immunophenotyping as Potential Biomarkers in Patients Undergoing Regional Nodal Irradiation for Breast Cancer

Robert Mutter
Female
18 years and over
This study is NOT accepting healthy volunteers
0000-122046-H01-RST
19-003532
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Histologically confirmed primary or recurrent invasive breast cancer with plans for adjuvant radiation therapy at the Mayo Clinic.
  • Oligometastatic breast cancer (≤ 3 sites of metastases) is permitted provided that the disease is managed with curative intent.
  • Patients treated with lumpectomy or mastectomy.
  • Patients must have indication for regional nodal irradiation.
  • Age 18 or older.
  • Willingness to provide informed consent and expresses understanding of this protocol and its requirements, risks, and discomforts.
  • Patients must have completed their final breast surgery including re-excision of margins for invasive cancer and DCIS or chemotherapy within 90 days prior to registration but no sooner than 21 days prior to the initiation of radiation therapy (RT).
  • Bilateral breast cancer is permitted.
  • Positive or close margins is allowed.


Exclusion Criteria:
 

  • Other active malignancy ≤ 2 years prior to registration (exceptions: non-melanotic skin cancer or carcinoma-in-situ of the cervix).
  • Pregnancy or lactation.
  • Inability on the part of the patient to understand the informed consent to be compliant with the protocol.

 

Breast cancer, Cancer, Ductal carcinoma in situ, Invasive lobular carcinoma, Recurrent breast cancer, Recurrent cancer
Breast cancer surgery, Genetic mutation, Lumpectomy, Malignant tumor of breast, Mastectomy, Medical Oncology, Radiation therapy, Radiation therapy for breast cancer, Recurrent primary malignant neoplasm of left female breast, Recurrent primary malignant neoplasm of right female breast, Secondary malignant neoplasm of female breast
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Biomarkers of Fluoroquinolone-induced Mitochondrial Toxicity

A Study to Evaluate Biomarkers of Fluoroquinolone-induced Mitochondrial Toxicity

Linda Hasadsri
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122066-H01-RST
19-003716
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • 18 years of age or older.
  • Treatment with oral and/or intravenous FQ antibiotics (ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin) that has been initiated upon, or within 24 hours of, admission to the HIM service or at time of initial Infectious Diseases consultation and lasting > 48 hours.
  • Arm 1: Treatment with oral and/or intravenous FQ antibiotics (ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin) that has been initiated upon, or within 24 hours of, admission to the HIM service or at time of initial Infectious Diseases consultation and lasting > 48 hours.
  • Arm 2: previously received FQ antibiotics in the past and symptomatic with a previous muscle or nerve biopsy after receiving FQ antibiotics.


Exclusion Criteria:
 

Arm 1:  Any of the following:

  • FQ antibiotic treatment that has been initiated > 24 hours prior to admission that has not yet been completed (e.g., patient is admitted or transferred to HIM or had ID consult when they are already on day 3 of a 7-day course of treatment).
  • Active cancer.
  • Chemotherapy or radiation therapy within the past 6 months.
  • Physical and/or cognitive impairment to the extent that patient cannot be fully assessed for or asked about symptoms of adverse reactions associated with fluoroquinolones.
  • Currently pregnant.
  • Blood transfusion within the past 4 months.
  • Previous bone marrow or organ transplant.
  • Currently on nucleoside reverse transcriptase inhibitors.
  • Pre-existing mitochondrial disease.
  • < 18 years of age.
  • Prior treatment with FQs within 1 week of admission.
  • Active history of routine alcohol use.

Arm 2:

  • Previously received FQ antibiotics in the past and not symptomatic.
  • Previously received FQ antibiotics in the past and there is no available clinical residual muscle or nerve biopsy.
  • < 18 years of age.

Eligibility last updated 6/17/22. Questions regarding updates should be directed to the study team contact.

General infectious diseases
4-quinolones adverse reaction, Antibiotic therapy, Ciprofloxacin, Delafloxacin, Depletion of mitochondrial DNA, Levofloxacin, Moxifloxacin, Poisoning by drug AND/OR medicinal substance, ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients (FMT in SOT (RECOVER))

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Sahil Khanna
All
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
0000-122068-P01-RST
19-003725
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Is able to provide written informed consent.
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Ability to take oral medication.
  • Male or female, at least 18 years of age.
  • Is a solid organ transplant (SOT) recipient.
  • Has recurrent C. difficile infection. A C. difficile recurrence is defined as:
    •  Positive C. difficile testing in stool (confirmed via medial record review) AND
    •  Diarrhea (≥3 loose stools over 24 hours) during the 180-day period following completion of treatment for prior CDI episode.
  • History of positive IgG testing to cytomegalovirus (CMV) and Epstein Barr Virus (EBV) for subject.
  • Clinical response to 4-10 days of C. difficile treatment for the current CDI episode. Clinical response is defined as ≥5% reduction of diarrhea.
  • Females of childbearing potential must have a negative urine or serum pregnancy test at baseline and prior to randomization. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Women of childbearing potential in sexual relationships with men must use an acceptable method of contraception§ from 30 days prior to enrollment until 4 weeks after completing study treatment. Males must agree to avoid impregnation of women during and for four weeks after completing study treatment through use of an acceptable method of contraception.
    • Note: Acceptable method of contraception is defined as those, alone or in combination, that result in a low failure rate [i.e. less than 1% per year] or in conjunction with their sexual partner(s), use 2 forms of medically acceptable contraceptive methods that have a reported failure rate of >1% per year. Includes, but is not limited to, barrier with additional spermicidal foam or jelly, intrauterine device, hormonal contraception (started at least 30 days prior to study enrollment), intercourse with men who underwent vasectomy.

 


Exclusion Criteria:

  • Major bowel resection surgery within 90 days of randomization.
  • Active chronic intestinal disease (e.g. Crohn's disease, ulcerative colitis).
  • History of total colectomy or bariatric surgery.
  • Known or suspected toxic megacolon and/or known small bowel ileus.
  • Presence of colostomy or ileostomy.
  • Concomitant antibiotic use within 48 hours of Visit 2. Topical antibiotics and SOT prophylaxis (e.g., trimethoprim-sulfamethoxazole) are permitted.
  • Dysphagia: oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, ALS), or patient shows evidence of dysphagia when the ‘safety test’ capsule is administered.
  • Currently receiving medication for treatment of acute rejection and/or develop acute rejection prior to administration of FMT.
  • Active, severe gastroparesis
  • Unwilling to withhold probiotics for duration of study. Probiotics include supplements, prescriptions, and non-prescriptions. Foods (like yogurt) are permitted.
  • Neutropenia, ≤500 neutrophils/mL [abstracted from the medical record and resulted within 7 days of Visit 2].
  • Symptomatic co-infection with another intestinal pathogen as determined by chart review.
  • Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy. Patients on maintenance chemotherapy may be enrolled only after consultation with medical monitor.
  • Any severe food allergy, defined as a history of anaphylaxis, systemic urticarial or angioedema attributed to a food and requiring current avoidance precautions.
  • Expected life expectancy <6 months.
  • Use of investigational drugs, biologics, or devices within 30 days prior to randomization.
  • Women who are pregnant, lactating or planning on becoming pregnant during the study.
  • Not suitable for study participation due to other reasons at the discretion of the investigators        
Drug, Fecal microbiota transplantation
C. difficile infection, General infectious diseases
Fecal transplant, Recurrent Clostridium difficile infection, Transplant present, Vancomycin, vancomycin
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Adolescent Autonomic Dysfunction Registry and Biobank

A Study to Create an Adolescent Autonomic Dysfunction Registry and Biobank

Kelsey Klaas
All
12 years to 18 years old
This study is NOT accepting healthy volunteers
0000-122072-H01-RST
19-003773
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female patients with presenting symptoms suggestive of Adolescent Autonomic Dysfunction.
  • Able to provide Informed Consent (or parental ability to provide informed consent if under age 18).
  • Has a Mayo Clinic Number.


Exclusion Criteria:

  • Individuals who are unable to sign consent (e.g., mentally challenged, those declared legally incompetent, non-English speaking) or whose parents are unable to provide informed consent if under age 18.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Pilot Investigation of the Utility of Diaphragm Muscle Shear Wave Elastography to Assess Opioid-Induced Respiratory Depression

A Study to Assess Opioid-Induced Respiratory Depression Using Diaphragm Muscle Shear Wave Elastography

Carlos Mantilla
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122075-H01-RST
19-003798
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult male and non-pregnant women 18 years old or older.
  • Subject is able to understand the study procedure and provide informed consent.


Exclusion Criteria:
 

  • Subject is pregnant or breast feeding.
  • Patient pregnancy status will be obtained through standard of care at Mayo Clinic per Pre-Procedure Pregnancy Reasonably Excluded Guide (PREG) protocol: http://mayoweb.mayo.edu/sp-forms/mc2700-mc2799/mc2722-13.pdf.
  • Subject is unable to provide informed consent.
  • Subject has a pre-existing respiratory condition.
Respiratory failure
Decreased respiratory function, Drug groups primarily affecting central nervous system adverse reaction, Drug-related disorder, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Electrophysiological Measurements in Cochlear Implant Patients

A Study to Evaluate Electrophysiological Measurements in Cochlear Implant Patients

Aniket Saoji
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122077-H01-RST
19-003809
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Meets centers’ normal candidacy requirements for cochlear implantation or has already received their cochlear implant.
  • Must be able to provide consent to participate.


Exclusion Criteria:
 

  • For participants that have not yet received their cochlear implant.
  • A cochlear abnormality that might prevent insertion of the electrode array.
  • Additional handicap that would limit the patient from being able to follow study instructions.
Cochlear implant procedure, Cochlear prosthesis in situ, Electroacoustic assessments of hearing aid, Hearing test
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Phase II study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Scott Lester
All
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
0000-122094-P01-RST
19-003990
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • ≥ 18 years of age.
  • Histologic documentation of stage I-IV diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS), as defined by the 2016 WHO classification. This would include all entities within this category including germinal center B-cell and non-germinal center B-cell subtypes and those with a double expressor phenotype. Also eligible are stage I-IV high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements and high-grade B-cell lymphoma, NOS.
  • Completion of at least 3 cycles of a rituximab-containing, anthracycline-based combination chemotherapy regimen (R-CHOP preferred but not mandated).
  • Negative post-chemotherapy PET-CT scan or negative interim PET-CT scan performed within 2 weeks of the final cycle of chemoimmunotherapy. This is defined as a score of 1-3 on the PET Five Point (Deauville) Scale using the Modified Lugano Response Criteria for Non-Hodgkin’s Lymphoma.
  • ANC ≥ 1000 and platelet count ≥ 40,000.
  • Negative serum pregnancy test in women of child-bearing potential within 24 hours of initiating RT.
  • Signed study-specific informed consent.


Exclusion Criteria:

  • Primary central nervous system lymphoma, primary cutaneous DLBCL, leg type, T-cell/histiocyterich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, or other distinct non-Hodgkin lymphomas arising from large B-cells included in the WHO classification.
  • Any absolute contraindications to irradiation.
Radiation, Radiation oncology AND/OR radiotherapy
Cancer, Diffuse large b-cell lymphoma, Lymphoma, Non-Hodgkin's lymphoma
Cancer treatment, Diffuse non-Hodgkin's lymphoma, large cell (clinical), Hematopoietic system, High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, Medical Oncology, Radiation therapy
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Understanding the challenges, behavioral patterns, and preferences towards participation in clinical trials in minority patient populations: Development and validation of a personalized clinical trial educational platform to boost participation among underserved cancer patients.

Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations

Rahma Warsame
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
0000-122099-H01-RST
19-004014
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Subjects must be adults with age ≥ 18 years at the time of study entry.
  • Subjects with any cancer diagnosis may be included.
  • Subjects must be identified as new patients to hematology oncology at Mayo Clinic Florida, Arizona, Rochester, and Mayo Clinic Cancer Center at St. Vincent’s.
  • Subjects must be willing to provide informed consent for the study.


Exclusion Criteria:
 

  • Patients reported to have an estimated life-expectancy of  < 6 months, as assessed by their clinician.
  • Patients not willing to complete the Clinical Trials Study survey.
Behavioral, Research data collection
Adrenal cancer, Ampullary cancer, Anal cancer, Bladder cancer, Bone cancer, Brain tumor, Breast cancer, Cancer, Cancer of unknown origin, Cervical cancer, Cholangiocarcinoma, Colon cancer, Endometrial cancer, Esophageal cancer, Esthesioneuroblastoma, Fallopian tube cancer, Gallbladder cancer, Head and neck cancer, Hodgkin lymphoma, Kidney cancer, Leukemia, Liver cancer, Lung cancer, Lymphoma, Melanoma, Merkel cell carcinoma, Mesothelioma, Multiple myeloma, Neuroendocrine carcinoma, Non-Hodgkin's lymphoma, Non-melanoma skin cancer, Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer, Parathyroid cancer, Peritoneal cancer, Prostate cancer, Rectal cancer, Recurrent cancer, Retinoblastoma, Salivary gland cancer, Sarcoma, Skin cancer, Soft tissue sarcoma, Stomach cancer, Testicular cancer, Thyroid cancer, Ureteral cancer, Vaginal cancer, Vulvar cancer, Appendix cancer, Neuroendocrine tumor
Digestive system, Endocrine system, Hematopoietic system, Integumentary system, Malignant neoplastic disease, Medical Oncology, Musculoskeletal system, Nervous system, Reproductive system, Respiratory system, Urinary system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

BMT CTN 1704: Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM)

A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM)

William Hogan
All
60 years and over
This study is NOT accepting healthy volunteers
0000-122104-P01-RST
19-004029
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Subjects 60 years of age or older.
  • Able to speak and read English, Spanish or Mandarin.
  • Eligible for first allogeneic transplantation based on institutional standards.
  • Subjects must have a planned allogeneic transplantation for a hematologic malignancy.
  • Any allogeneic graft source or donor type will be permitted. Subjects must provide informed consent.
Other, Allogeneic bone marrow transplantation
Cancer, Leukemia, Lymphoma, Transplant disorder
Allogeneic stem cell transplant, Awaiting transplantation of bone marrow, Bone marrow transplant, Cancer treatment, Disease relapse in transplant marrow, Hematopoietic system, Malignant tumor of lymphoid hemopoietic and related tissue, Medical Oncology, Neoplasm of hematopoietic cell type
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Clonal Diversity of Freshly Taken ESD Specimens

A Study to Assess Clonal Diversity of Freshly Taken ESD Specimens

Prasad Iyer
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122111-H01-RST
19-004110
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients with Barrett’s Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment.


Exclusion Criteria:
 

  • Patients without BE or EAC or that are not planned for ESD treatment.
Barrett's esophagus, Cancer, Esophageal cancer
Adenocarcinoma of esophagus, Barrett's esophagus, Digestive system, Endoscopic procedure, Medical Oncology
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Evaluation of Potential Myocardial Injury in Patients with Cardiac Implantable Electronic Devices Following Magnetic Resonance Imaging

A Study to Evaluate Potential Myocardial Injury Following Magnetic Resonance Imaging (MRI)

Allan Jaffe
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122124-H01-RST
19-004286
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients 18 years or older.
  • Patients who have cardiac implantable electronic devices (CIED), whether conditional or unconditional, regardless of the type of device; e.g., ICD, pacemakers, leadless pacemakers, who undergo magnetic resonance imaging (MRI) for any reason.


Exclusion Criteria:
 

  • Patients under age 18.
  • Patients with myocardial infarction, coronary artery bypass grafting or any invasive cardiac procedure in the previous six weeks.
  • Pregnant patients.
  • Patients who cannot provide informed consent because of cognitive dysfunction.
Heart disease
Cardiac MRI, Cardiac implant in situ, Cardiovascular system, Complication due to imaging of patient with implanted medical device, MRI, Myocardial disease, Myocardial lesion
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Evaluation of Potential Myocardial Injury Following Elective Direct Current Cardioversion for Atrial Arrhythmias

A Study to Evaluate Potential Myocardial Injury Following Elective Direct Current Cardioversion

Allan Jaffe
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122125-H01-RST
19-004287
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients who are undergoing elective direct current cardioversion, either externally or via the patient’s internal cardioverter-defibrillator.


Exclusion Criteria:
 

  • Patients under age 18.

  • Patients with myocardial infarction, coronary artery bypass grafting or any invasive cardiac procedure in the previous six weeks.

  • Pregnant patients.

  • Patients who cannot provide informed consent because of cognitive dysfunction.

 

Atrial fibrillation, Atrial flutter, Heart arrhythmias, Heart disease, Heart arrhythmia
Atrial arrhythmia, Cardiac implant in situ, Cardiovascular system, Cardioversion, Complication associated with cardiac implant, Complication due to imaging of patient with implanted medical device, Myocardial disease, Myocardial lesion
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Pilot Study Evaluating Endometriosis with 16a-(18)F-fluoro-17ß-estradiol (F-18 FES) PET/MRI

A Study to Evaluate Endometriosis with PET/MRI

Ann Bender
Female
18 years to 50 years old
Phase 1/2
This study is NOT accepting healthy volunteers
0000-122133-P01-RST
19-004345
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Premenopausal women (18-50 years old).
  • Subjects with endometriosis.


Exclusion Criteria:
 

  • Postmenopausal women.
  • AP diameter when lying supine greater than 32 cm 
  • Unable to undergo PET/MRI for any reason (metal implants, severe claustrophobia)
  • Unable to receive IV Gadolinium contrast for any reason (renal failure eGFR < 60, contrast allergy)
  • Pregnant 
Drug, MRI of pelvis, PET/MRI system, Positron emission tomography
Endometriosis
Endometriosis, Fluoroestradiol F-18, PET/MRI scan, Reproductive system, fluoroestradiol F-18
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Patient Specific Induced Pluripotent Stem Cell Models for Spinal Muscular Atrophy (SMA)

A Study to Evaluate Pluripotent Stem Cell Models for Spinal Muscular Atrophy (SMA) Patients

Nathan Staff
All
up to 100 years old
This study is NOT accepting healthy volunteers
0000-122136-H01-RST
19-004374
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients aged 0-100 years with clinically diagnosed spinal muscular atrophy (SMA).
  • Subjects aged > 18 years who are biologically related to an individual clinically diagnosed with SMA.


Exclusion Criteria:
 

  • Subjects who are not clinically diagnosed with SMA and are not biologically related to an individual diagnosed with SMA.
  • Unaffected children < 18 years of age are ineligible for this study.
  • Patients with an allergy to subcutaneous lidocaine or bupivacaine (if undergoing a dermal punch biopsy).
  • Subjects unable to consent to the study (or have both parents/guardian/witness sign on their behalf).

 

Spinal muscular atrophy, Neuromuscular disorder
Nervous system, Spinal muscular atrophy
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

The PROP-RD Study: A Prospective Registry for the Study of Outcomes and Predictors in Pouchitis and Pouch-Related Disorders

A Study to Develop a Registry for Outcomes and Predictors in Pouch-Related Disorders

Laura Raffals
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122138-P01-RST
19-004405
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients with pouch-related disorders will be recruited from participating sites at the time of clinic visits.
  • At the time of enrollment, patients will be classified as having one of four inflammatory pouch conditions (acute pouchitis, CADP, CARP, or CD of the pouch).
  • All visits will be standard of care visits, where patients are identified as potential candidates for enrollment based on presentation with a pouch-related diagnosis.
  • Following the initial recruitment and data collection, patients will complete online questionnaires at 3, 6, and 12 months following enrollment in the prospective pouch registry.
Crohn's disease, Inflammatory bowel disease, Pouchitis
Ileal pouchitis, Digestive system, Inflammatory bowel disease
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair

Invasive Hemodynamic Response to Transcatheter Edge-to-Edge Mitral Valve Repair

Mackram Eleid
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122143-H01-RST
19-004449
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults, age ≥ 40 years.
  • Severe, symptomatic primary mitral regurgitation identified by Doppler transthoracic echocardiogram:
    • Heart team (cardiologist and cardiac surgeon) agree that patient would be eligible for TMVR with MitraClip.
    • TMVR procedure will be performed in the cardiac catheterization laboratory for hemodynamic data recording.


Exclusion Criteria:

  • None.
Heart valve disease, Mitral valve disease, Mitral valve regurgitation
Cardiovascular system, Decreased cardiac output, Diastolic dysfunction, Echocardiogram, Hemodynamic monitoring, Mitral valve regurgitation, Mitral valve repair and replacement, Pulmonary venous congestion, Right ventricular function - finding, Transthoracic echocardiogram
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) Imaging In Supine Patients

A Study to Evaluate Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) Imaging In Supine Patient

Lauren Dalvin
All
Not specified
This study is NOT accepting healthy volunteers
0000-122144-H01-RST
19-004452
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Medical indication for examination under anesthesia and OCT/OCTA imaging, including an ocular oncology or retinal disorder, such as retinoblastoma.
  • Control images will be obtained from patients with an indication for OCT/OCTA imaging who are able to cooperate for images in the office.


Exclusion Criteria:
 

  • Patients who do not have a medical indication for OCT/OCTA imaging.
Cancer, Retinal disease, Retinoblastoma
Medical Oncology, Neoplasm of eye proper, Optical coherence tomography, Retinal disorder, Retinoblastoma, Supine body position
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Development and Assessment of the Role of Artificial Intelligence (AI) in MR Fingerprinting of the Brain

A Study to Develop and Assess the Role of Artificial Intelligence in MR Fingerprinting of the Brain

Kiaran Mcgee
All
18 years to 100 years old
This study is NOT accepting healthy volunteers
0000-122147-H01-RST
19-004479
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Patients over the age of 18 years old.


Exclusion Criteria:
 

  • Children.
MRI
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) (ALLFTD)

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Bradley Boeve
All
18 years and over
This study is NOT accepting healthy volunteers
0000-122152-H01-RST
19-004543
Show full eligibility criteria
Hide eligibility criteria

General

Inclusion Criteria:

  • Referring diagnosis of an FTLD clinical syndrome (see below) or a member of a family with a strong medical history of an FTLD syndrome.
  • Age 18 years of age or greater (preferably at least 30 because symptoms rarely develop before then).
  • Have a reliable study partner who can provide general information about behavior and feelings/emotions, and an independent evaluation of functioning.
  • Must, in the opinion of the site investigator, be able to complete a majority of study procedures.

Longitudinal Arm

Inclusion Criteria:

  • All longitudinal arm participants must speak English or Spanish (consents will be translated) as a primary language. Many of the clinical and neuropsychological scales required for ALLFTD are unvalidated in languages other than English or Spanish, rendering the data unusable for cross-sectional comparisons.

Familial FTLD Participants:

  • Members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes) OR an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.
  • Participants will be enrolled based on membership in these families and not individual genotype status, and knowledge of personal genotype status (in families with known mutations) is not required for participation.
  • Each center will evaluate the eligibility of candidates prior to enrollment through a phone interviewing process, or via direct contact with the center or laboratory including establishing symptom severity (this may be conducted by phone interview for screening purposes). All familial enrollees will be made aware that they are being enrolled because of family history and/or because of a known mutation in the family; no participant has to be aware of their own genetic status to participate.
  • Familial participants may be asymptomatic or symptomatic; all assessments are the same regardless of the presence or absence of symptoms. Because genetically-mediated FTLD syndromes may manifest in heterogeneous and diverse ways, participants do not have to meet research criteria for a known FTLD syndrome to be included.

Sporadic FTLD Participants:

  • Sporadic participants should be symptomatic with no known family history or genetic mutation to indicate f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:

    • Progressive Supranuclear Palsy: Inclusion criteria for progressive supranuclear palsy are based upon the 2017 Movement Disorders Society Consensus Criteria (full criteria can be found in the Manual of Procedures).29 These criteria for probable or possible PSP of either typical (Richardson’s) or variant syndromes are defined based on criteria plus 2 or 3 features below:
      • Core Features:
        • History of postural instability;
        • Ocular motor deficits  (supranuclear gaze palsy);
        • Akinesia;
        • Cognitive dysfunction and/or a speech/language disorder.
    • Semantic variant Primary Progressive Aphasia (svPPA): The core features of svPPA include:
      • a language disorder characterized by progressive, fluent, empty spontaneous speech, and semantic paraphasias;
      • selective impairment of semantic memory causing anomia, impaired spoken and written single word comprehension, and an impoverished fund of general information;
      • relative sparing of syntax and phonology; and
      • normal visuospatial abilities. 
    • Corticobasal Syndrome (CBS). Inclusion criteria for CBS are based on the probable or possible CBD criteria by Armstrong et al.30
      • for probable CBS: insidious onset after age 50, at least a 12 month history of symptoms: Asymmetric presentation of at least 2 of the following: limb rigidity or akinesia, limb dystonia, limb myoclonus, plus 2 of: orobuccal or limb apraxia, alien limb phenomenon, cortical sensory loss;
      • insidious onset with no minimum age; at least one year history of at least one of: limb rigidity or akinesia, limb dystonia, limb myoclonus, plus 2 of: orobuccal or limb apraxia, alien limb phenomenon, cortical sensory loss. Symptoms may be symmetric.
    • Behavioral variant Frontotemporal dementia (bvFTD). Inclusion criteria for bvFTD are based on consensus criteria. The primary features are early decline in regulation of personal and social and interpersonal conduct, emotional blunting, and loss of insight. Specifically, early presentation (first six months) must be characterized by at least five of the following: loss of insight, disinhibition, restlessness, distractibility, emotional lability, reduced empathy or unconcern for others, lack of foresight and planning, impulsivity, social withdrawal, apathy or lack of spontaneity, poor self-care, reduced verbal output, verbal stereotypies or echolalia, perseveration, overeating or excessive fluid intake, and sexual hyperactivity.
    • Nonfluent variant Primary Progressive Aphasia (nfvPPA) subtype: The primary clinical features in nfvPPA are non-fluent spontaneous speech with agrammatism, phonemic paraphasias, and anomia. Other features include problems with speech initiation, and finding and sequencing of articulatory movements. Comprehension is relatively well preserved, although difficulty following syntactically complex commands may be present.
    • Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD/ALS): A diagnosis of FTD-ALS relies on meeting diagnostic criteria for possible bvFTD or PPA plus clear evidence of ALS on physical examination, such as weakness, muscle atrophy, fasciculations, and elevated reflexes as described in the El Escorial diagnostic criteria for ALS, but not necessarily meeting probable ALS criteria. EMG is not required for diagnosis

Biofluid-Focused Arm

Inclusion Criteria:

  • Participants enrolled in the biofluid arm may be either f-FTLD or s-FTLD.
  • All general inclusion criteria apply.
  • Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria.
  • Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available.


Exclusion Criteria:

Exclusion criteria are evaluated at the site investigator’s discretion; if the site investigator believes that the participant’s symptoms are due to FTLD despite the presence of an exclusionary condition, the investigator may overrule the exclusion.

  • Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.
  • Known presence of an Alzheimer’s disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer’s disease as a cause of the clinical syndrome.
  • A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.
  • Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 < 95% of local laboratory’s normal value), unregulated hypothyroidism (TSH >150% of normal), HIV positive, renal failure (creatinine > 2), liver failure (ALT or AST > two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.
  • Current medication likely to affect CNS functions in the opinion of the site PI.
  • In the site investigator’s opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.
Frontotemporal dementia
Frontotemporal degeneration, GRN-related frontotemporal dementia, Nervous system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Randomized Controlled Trial to Evaluate Efficacy of Psychological Support Based on Positive Suggestions (PSBPS) on Mental Health Morbidity and Cognitive Function (PSBPS)

A Study to Evaluate the Effectiveness of Psychological Support Based on Positive Suggestions on Mental Health Morbidity and Cognitive Function

Lioudmila Karnatovskaia
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
0000-122165-H01-RST
19-004660
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Critically ill patients with either ARF on mechanical ventilation or requiring vasopressors or both  admitted to the ICU and expected ICU stay > 48 hours.


Exclusion Criteria:
 

  • Patients with a history of dementia.
  • Patients with intellectual disability.
  • Patients who have attempted suicide.
  • Patients with psychotic disorders such as schizophrenia, acute alcohol/substance intoxication or withdrawal.
  • Patients with severe metabolic encephalopathy.
  • Patients with any form of cognitive impairment significant enough to preclude patient from completing study questionnaires.
  • Patients on comfort care.
  • Patients not expected to survive the hospital stay.
  • Non-English speaking patients.
Artificial respiration, Emotional support, Implementation of measures to provide psychological support, Behavioral
Acute respiratory failure, Respiratory failure
Acute respiratory failure, Intensive care psychiatric disorder, Mechanical ventilation, Patient requires hospitalization, Patient status determination, critical, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Retinoblastoma Patient Clinical Database and Tissue Repository

A Study to Establish a Retinoblastoma Patient Clinical Database and Tissue Repository

Lauren Dalvin
All
up to 17 years old
This study is NOT accepting healthy volunteers
0000-122166-H01-RST
19-004663
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • All subjects, 1 month to 17 years old.
  • Subjects with a diagnosis or history of unilateral or bilateral retinoblastoma.


Exclusion Criteria:

  • Su bjects less than 31 days old or 18 years of age and older.

 

Cancer, Retinoblastoma
Medical Oncology, Retinoblastoma
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies

A Study to Evaluate the Feasibility of Intraoperative Microdialysis (tissue sampling) during Neurosurgery for Central Nervous System Malignancies

Terence Burns
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
0000-122168-P01-RST
19-004694
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age > 18 years old.
  • ECOG performance status (PS) 0, 1 or 2.
  • Clinical and radiographic evidence suggesting a diagnosis of a diffuse glioma, or a prior diagnosis of a diffuse glioma.
  • Diffuse gliomas include diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma and anaplastic oligodendroglioma.
  • Planned neurosurgical procedure for purposes of biopsy or resection of suspected or previously diagnosed brain tumor as part of routine clinical care.
  • Willing to undergo neurosurgical resection or biopsy at Mayo Clinic (Rochester, MN).
  • Ability to understand and the willingness to sign a written informed consent document.

 


Exclusion Criteria:

  • Vulnerable populations:
    • Pregnant women;
    • Prisoners;
    • Mentally handicapped.
  • Patients who are not appropriate candidates for surgery due to current or past medical history or uncontrolled concurrent illness.

 

Procedure/Surgery, Biopsy of brain tissue tumor, Excision of neoplasm of central nervous system, Intraoperative care, Microdialysis system
Astrocytoma, Brain lesions, Brain tumor, Cancer, Central nervous system disorder, Glioblastoma, Glioblastoma multiforme, Glioma, Oligodendroglioma
Anaplastic astrocytoma of central nervous system, Brain tumor surgery, Cancer treatment, Glioblastoma multiforme of central nervous system, Grade 2 astrocytoma of brain, Medical Oncology, Nervous system, Oligodendroglioma, Oligodendroglioma, anaplastic, Central nervous system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN